Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 2 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

PTSD linked to increased risk of hypothyroidism among women

19 Nov 2019

Women with post-traumatic stress disorder (PTSD) are at increased risk of developing thyroid dysfunction, a study reports.

The study included 45,992 women from the ongoing Nurses’ Health Study II. Thirty percent of these women reported having no history of traumatic events, 50 percent reported being exposed to trauma with no PTSD symptoms, and 4 percent reported the highest number (6–7) of PTSD symptoms.

Relative to those who did not experience any trauma, women with the highest number of PTSD symptoms were more likely to have the highest somatotype at age 5 years, have a higher body mass index, smoke frequently, use oral contraceptives, be menopausal, and use ibuprofen medication and antidepressants.

Over a follow-up of 24 years, hypothyroidism occurred in 7,993 women and Graves’ hyperthyroidism in 847. Hypothyroidism showed a dose-response association with PTSD symptoms, with the incidence higher in the group of women presenting with a greater number of PTSD symptoms. This was not observed for Grave’s hyperthyroidism.

In multivariable Cox models, the hazard ratios for hypothyroidism were 1.08 (95 percent confidence interval [CI], 1.02–1.15) in women with trauma with no PTSD symptoms; 1.12 (95 percent CI, 1.04–1.21) in those with 1–3 PTSD symptoms; 1.23 (95 percent CI, 1.13–1.34) in those with 4–5 symptoms; and 1.26 (95 percent CI, 1.14–1.40) with 6–7 symptoms (p-trend<0.001).

The association persisted in sensitivity analyses restricted to outcomes with onset after 2008 when PTSD was assessed.

The present data underscore the importance of awareness for thyroid dysfunction in women with PTSD, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 2 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.